{{Rsnum
|rsid=612224
|Chromosome=2
|position=31586801
|Orientation=plus
|GMAF=0.3021
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(G;G)
|geno2=(G;T)
|geno3=(T;T)
}}{{ population diversity
| geno1=(G;G)
| geno2=(G;T)
| geno3=(T;T)
| CEU | 8.8 | 33.6 | 57.5
| HCB | 27.7 | 44.5 | 27.7
| JPT | 6.2 | 51.3 | 42.5
| YRI | 2.0 | 29.9 | 68.0
| ASW | 5.3 | 29.8 | 64.9
| CHB | 27.7 | 44.5 | 27.7
| CHD | 17.6 | 48.1 | 34.3
| GIH | 12.9 | 44.6 | 42.6
| LWK | 1.8 | 30.9 | 67.3
| MEX | 13.8 | 46.6 | 39.7
| MKK | 1.9 | 25.0 | 73.1
| TSI | 11.8 | 48.0 | 40.2
| HapMapRevision=28
}}{{PMID Auto
|PMID=23499746
|Title=SRD5A1 and SRD5A2 are associated with treatment for benign prostatic hyperplasia with the combination of 5α-reductase inhibitors and α-adrenergic receptor antagonists
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}